Paclitaxel alone and paclitaxel plus bevacizumab are both active as treatments for patients with advanced angiosarcoma, but the addition of bevacizumab does not provide any additional benefit over paclitaxel alone, a new study published in the Journal of Clinical Oncology has shown.

For the phase 2 trial, researchers enrolled 52 patients with advanced angiosarcomas. Of those, 50 patients were randomly assigned to receive paclitaxel 90 mg/m2 weekly for six 28-day cycles or paclitaxel plus bevacizumab 10 mg/kg every 2 weeks. Patients in the combination arm then received bevacizumab maintenance therapy 15 mg/kg every 3 weeks until disease progression or unacceptable toxicity.

Of the 50 patients that received treatment, 49% had their primary disease site in the breast and 12% of patients had primary disease site in the skin. In addition, 34% of patients had visceral disease and 49% of patients had radiation-induced angiosarcoma.

Continue Reading

During a median follow-up time of 14.5 months, results showed that 6-month progression-free survival rates were 54% and 57% in the paclitaxel alone arm and the combination arm, respectively. The median overall survival rates were 19.5 months and 15.9 months, respectively.

RELATED: Frequent, Actionable MET Gene Mutations Found in Pulmonary Sarcomatoid Carcinoma

In regard to safety, the frequency of adverse events was higher in the combination arm and one patient in the combination arm died due to treatment-related intestinal occlusion.

The findings suggest that no additional investigation is warranted to study paclitaxel plus bevacizumab for the treatment of patients with advanced angiosarcomas.


  1. Ray-Coquard IL, Domont J, Tresch-Bruneel E, et al. Pacltaxel given once per week with or without bevacizumab in patients with advanced angiosarcoma: a randomized phase II trial. J Clin Oncol. 2015. [epub ahead of print]. doi: 10.1200/JCO.2015.60.8505.